Skip to main content
DeutschDE
European Commission logo print header

INtestinal Tissue ENgineering Solution

Ziel

Short Bowel Syndrome (SBS) is a condition that occurs when part or the entire small intestine is missing or has been removed during surgery. This condition renders the bowel incapable of fulfilling its nutritional function (intestinal failure). There is no cure for SBS. Parenteral (intravenous) nutrition (PN) and bowel transplantation are currently the preferred options for nutrition in children and adults who have lost their bowel. PN offers a low survival rate, compromised quality of life, and the economic cost for each patient is estimated to be 55,000 euro/year. Small intestinal transplant is also an option with one-year and 4-year survival rates of 90% and 60% respectively. However, because of the shortage of organs, high mortality, the severe side effects of immunosuppression and low quality of life, this is still a sub-optimal solution. The objective of this programme is to deliver a functional bowel reconstruction option to patients with SBS through an autologous tissue engineering strategy, overcoming the shortage of organs, and avoiding the need for immunosuppression. It will be achieved by identifying the best autologous cell source; providing the ideal scaffold; engineering functional intestinal mucosa for transplantation and engaging with patients, scientists and public. The work is designed to lead directly to a clinical trial for the application of the optimal protocol for tissue-engineered intestinal mucosa. The consortium is uniquely positioned to complete this ambitious effort as we have an internationally pre-eminent, multi-disciplinary team, which possesses a combination of expertise from basic molecular biology, engineering, and surgery, combining knowledge from universities, hospitals and industry. Importantly we are one of the few groups in the world with experience, infrastructure, and track record to translate regenerative medicine solutions to patients, including true clinical translation of tissue engineered organs.

Wissenschaftliches Gebiet

Schlüsselbegriffe

Programm/Programme

Thema/Themen

Aufforderung zur Vorschlagseinreichung

H2020-PHC-2014-2015

Andere Projekte für diesen Aufruf anzeigen

Unterauftrag

H2020-PHC-2015-two-stage

Finanzierungsplan

RIA - Research and Innovation action

Koordinator

UNIVERSITY COLLEGE LONDON
Netto-EU-Beitrag
€ 1 569 546,00
Adresse
GOWER STREET
WC1E 6BT London
Vereinigtes Königreich

Auf der Karte ansehen
Region
London Inner London — West Camden and City of London
Aktivitätstyp
Higher or Secondary Education Establishments
Links
Gesamtkosten
€ 1 569 548,25

Beteiligte (8)

Diese Seite teilen

Herunterladen

Letzte Aktualisierung: 23 November 2023

Mein Booklet

Permalink: https://cordis.europa.eu/project/id/668294/de

European Union, 2024